Citations

Clear

4847 citation(s) found for "Tu, Eric".

Characterizing early behavioral and social–emotional problems in young children with SCN1A + Dravet syndrome: Findings from the E
Scheffer, Ingrid E., Perry, M. Scott, Sullivan, Joseph , Boronat, Susana , Wheless, J. W., Brunklaus, Andreas , Laux, Linda C, Patel, Anup D. , Roberts, Colin, Dlugos, Dennis J., Holder, Deborah , Lallas, Matt, Phillips, Steven, Segal, Eric , Lal, Dennis , Wirrell, Elaine, Zuberi, Sameer M., Shaffer, Rebecca, Wojnaroski, Mary , Christensen, Sarah , James, Emma S., Huang, Norman, Gofshteyn, Jacqueline S. , Scheffer, Ingrid E. , Wheless, James W. , Shaffer, Rebecca C. , Scheffer, Ingrid E , Perry, Michael Scott , Wheless, James W , Dlugos, Dennis , Knupp, Kelly G , Phillips, Steven , Segal, Eric , Lal, Dennis , Wirrell, Elaine C , Zuberi, Sameer M , Shaffer, Rebecca , Wojnaroski, Mary , Berl, Madison , James, Emma S , Vila, Maria Candida , Gofshteyn, Jacqueline S , Rico, Salvador , Patel, Anup D , Brunklaus, Andreas , Laux, Linda , Roberts, Colin, Dlugos, Dennis , Knupp, Kelly G. , Phillips, Steven , Wirrell, Elaine , Zuberi, Sameer M. , Berl, Madison M. , James, Emma S. , Huang, Norman, Rico, Salvador

Mayo Clinic

Epilepsia | February 2, 2026 | Volume: 67 | Issue: 5 | Pages: 2463-2479

10.1002/epi.70127 | PMID 41627953 Get It

Abstract Objective Dravet syndrome (DS) is the prototypic developmental and epileptic encephalopathy, characterized by drug‐resistant seizures, developmental slowing, and many other morbidities. Detailed characterization of behavioral phenotypes and social–emotional skill development are limited. Methods We prospectively assessed behavioral and social–emotional problems in the ENVISION natural history study (NCT04537832) of children with DS associated with SCN1A pathogenic variants ( SCN1A + DS) enrolled at <5 years of age. Assessments every 3 months for up to 2 years included the Child Behavior Checklist (CBCL), Strengths and Difficulties Questionnaire (SDQ), Brief Infant‐Toddler Social and Emotional Assessment (BITSEA), and Vineland Adaptive Behavior Scales, 3rd Edition (VABS‐3). Results Fifty‐eight children with DS enrolled at 16 sites worldwide. Problematic behaviors—inattention, aggressive or oppositional behaviors, and withdrawn and autistic behaviors—began before age 3 years, became more evident with age, and were clinically significant in many children by age 3–4 years. CBCL Total, Externalizing, and Internalizing Problems T‐scores rose by approximately 3 points per year, and BITSEA Problem scale scores increased by 2.3 points annually ( p = .002). SDQ Hyperactivity scores worsened over time ( p = .013), whereas emotional difficulties remained stable. VABS‐3 Socialization domain scores, which were already more than 1 SD below the normative mean at baseline, decreased further, particularly in younger participants. Correlation analyses showed that poorer communication abilities were associated with increased problematic behaviors ( R = −.55 for CBCL Total Problems and VABS‐3 Communication scores). Mixed‐effects modeling identified age as the strongest predictor of worsening behavioral outcomes. Significance We found that behavioral and social–emotional problems are inherent components of DS that present in toddlerhood and worsen throughout early childhood. This highlights the need to diagnose and manage these issues early. Targeted therapy may alleviate the wide‐ranging morbidities that are intrinsic to DS, including the social–emotional and behavior problems that frequently emerge.
Present Electrically Evoked Compound Action Potentials and Lack of Auditory Sensation Through a Cochlear Implant After Vestibular Schwannoma Resection
Kolberg, Courtney, Babajanian, Eric E. , DeJong, Melissa D., Deep, Nicholas L. , Dornhoffer, James R. , Neff, Brian A., Driscoll, Colin L.W., Carlson, Matthew L., Saoji, Aniket A. , Kolberg, Courtney, Driscoll, Colin L. W., Carlson, Matthew L.

Mayo Clinic

Otology & Neurotology | February 2, 2026 | Volume: 47 | Issue: 4 | Pages: e623-e626

10.1097/mao.0000000000004846 | PMID 41622559 Get It

Objective: Auditory nerve monitoring through electrically evoked compound action potentials (eCAP) can be used to assess cochlear neural integrity during vestibular schwannoma (VS) resection. Herein, we report on 5 cochlear implant (CI) patients who underwent VS resection with present eCAP responses both intraoperatively and postoperatively. Patients either did not perceive any sound through their CI or rapidly adapted to electrical stimulation, suggesting that the presence of eCAP does not guarantee auditory nerve function in patients with VS resection. Patients: Five patients who underwent simultaneous VS translabyrinthine resection and cochlear implantation. Interventions: Simultaneous cochlear implantation and translabyrinthine microsurgical VS resection. Main outcome measure: Electrically evoked compound action potential. Results: All patients had eCAP responses present during their VS resection and for at least 50 days post-surgery. Three of the 5 patients did not perceive any sound with their cochlear implant. This shows that the presence of an eCAP alone does not guarantee a functional auditory nerve or auditory perception. The other 2 patients could hear non-speech sounds, but these sounds quickly became inaudible, indicating that their auditory nerve lacked the ability to integrate the electrical stimulus over time. Conclusions: The presence of an eCAP response does not guarantee auditory sensation through a CI. Although eCAP measurements provide insight into the function of the distal end of the nerve, it does not ascertain integrity or function of the larger auditory nerve pathway. Therefore, eCAPs should not be used in isolation to monitor auditory nerve function during VS resection.
Alterations in CSF Amyloid-β and Tau Biomarkers in Former College and Professional American Football Players: Findings from the DIAGNOSE CTE Research Project
Shofer, Jane B. , Colasurdo, Elizabeth A. , Li, Ge , Adler, Charles H., Balcer, Laura, Bernick, Charles, Daneshvar, Daniel, Katz, Douglas I., McClean, M M, Mez, Jesse, Palmisano, Joseph, Ashton, Nicholas, Blennow, K., Zetterberg, Henrik, Tripodis, Yorghos, Alosco, Michael L., Cummings, Jeffrey L., Reiman, EM, Shenton, Martha, Stern, Robert A., Iliff, Jeffrey J. , Peskind, Elaine R. , Jansson, Deidre , Schindler, Abigail G. , Adler, Charles H. , Bernick, Charles , Daneshvar, Daniel H. , Katz, Douglas I. , McClean, Michael D , Mez, Jesse , Palmisano, Joseph , Ashton, Nicholas J. , Blennow, Kaj , Zetterberg, Henrik , Tripodis, Yorghos , Alosco, Michael L. , Cummings, Jeffrey L. , Reiman, Eric M. , Shenton, Martha E.

Mayo Clinic

Journal of Neurotrauma | January 30, 2026 | Volume: 43 | Issue: 7-8 | Pages: 559-574

10.1177/08977151251390520 | PMID 41612558 Get It

Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease associated with exposure to repetitive head impacts (RHIs), characterized by tau tangles around small blood vessels at the depths of the sulci. Currently, CTE can be diagnosed only postmortem , but can present with an array of cognitive, behavioral, mood, and motor symptoms. However, traumatic brain injury is also associated with increased risk of Alzheimer’s disease (AD) and may lead to comorbid neuropathology. Characterization of the in vivo biomarkers of CTE is a necessary next step to facilitate accurate diagnoses. We examined the profile of cerebrospinal fluid (CSF) biomarkers of amyloid-β, total tau (tTau), and phospho-tau (pTau) in a cohort of former professional (PRO, n = 100) and college (COL, n = 40) football players at high risk of CTE compared to asymptomatic unexposed controls (UE, n = 43). CSF was collected under controlled conditions using collection, processing, and cryostorage kits provided by the DIAGNOSE CTE Research Project Biomarker Core, and concentrations of Aβ 40 , Aβ 42 , tTau, and pTau (pTau 181 , pTau 217 , pTau 231 ) were measured at the University of Gothenburg, Sweden, using immunoassays. Associations between CSF biomarker levels with football history, and diagnosis of traumatic encephalopathy syndrome (TES) were examined using linear regression, and corrected for age, education, APOE -ε4 allele status, race, and body mass index. Our analysis revealed that football exposure affected both CSF Aβ 40 ( p = 0.039) and Aβ 42 ( p = 0.038), particularly among those under 60 years of age in the PRO compared to the UE exposure group. Among former football players, estimates of RHI exposure were not generally associated with CSF Aβ, tTau, and pTau biomarker levels. CSF Aβ 40 ( p = 0.0041) and Aβ 42 ( p = 0.011) were lower in former football players with TES diagnosis compared to unexposed participants, although CSF Aβ, tTau, and pTau biomarker levels did not differ between former players with and without a TES diagnosis. Among former football players, reduced CSF Aβ 40 ( p = 0.011) and Aβ 42 (p = 6e-04) were observed in those with cognitive impairment compared to those with neurobehavioral dysregulation. The findings of significant associations of reduced CSF Aβ levels with RHI in elite football players are in line with recent postmortem studies; however, the lack of relationship with CSF tTau and pTau species observed to be altered in the setting of AD suggests that the pathological features of CTE reflected in fluid biomarkers are complex and require further study. The overlapping comorbid age-dependent features of neurodegeneration that occur in those at risk for CTE suggest that tau pathology in CTE is not reliably reflected by currently available fluid biomarkers and that the use of multiple biomarkers related to the compound characteristics of CTE may be required for early detection.
Percutaneous Left Atrial Appendage Occlusion for Atrial Fibrillation in Cardiac Amyloidosis
Almakadma, Abdul Hakim , Ibrahim, Ramzi, Pham, Hoang Nhat, Habib, Eiad, Mahmoud, Ahmed K., Awad, Kamal, Bhakta, Mayurkumar D. , Yang, Eric H., Masry, Hicham Z. El, Ayoub, Chadi, Arsanjani, Reza, Ayoub, Chadi , Masry, Hicham El , Awad, Kamal , El Masry, Hicham , Ayoub, Chadi , Ibrahim, Ramzi , Pham, Hoang Nhat , Habib, Eiad , Mahmoud, Ahmed K , Awad, Kamal , Yang, Eric H. , Arsanjani, Reza

Mayo Clinic

Journal of Arrhythmia | January 27, 2026 | Volume: 42 | Issue: 1 | Pages: No page available

10.1002/joa3.70274 | PMID 41607868 Get It

ABSTRACT Background Cardiac amyloidosis (CA) is frequently complicated by atrial fibrillation (AF), yet outcomes after left atrial appendage occlusion (LAAO) in this population remain poorly defined. Methods We conducted a retrospective TriNetX study of adults with AF undergoing LAAO, comparing patients with and without CA after 1:1 propensity matching. Outcomes were assessed using Kaplan–Meier analyses and Cox regression. Results Among 532 matched pairs, mortality and major adverse cardiovascular events were similar between groups, whereas major bleeding was higher in CA (HR 1.90). Conclusions LAAO yields comparable ischemic outcomes in CA, though bleeding risk is increased.
Phase 1b/2 study of BMS-813160, a CCR2/5 dual antagonist, in combination with chemotherapy or nivolumab in patients with advanced pancreatic or colorectal cancer
Folprecht, G., Varghese, Anna M. , Gutiérrez, Martín , Noel, Marcus Smith , Chen, Eric, Dayyani, Farshid, Davis, S Lindsey, BasuMallick, Atrayee, Garrido-Laguna, Ignacio, Osawa, Mayu, O’Brien, Shaun, Novosiadly, Ruslan D., Xu, Ke, Greenawalt, Danielle , Dutta, Santanu, Victor, Christina Twyman Saint, Lenz, Heinz-Josef, Folprecht, Gunnar , Chen, Eric , Osawa, Mayu , Le, Dung Thi , Trikalinos, Nikolaos A. , Chen, Eric X. , Dayyani, Farshid , Davis, S Lindsey, Wee, Wen , Garrido‐Laguna, Ignacio , O’Brien, Shaun, Dutta, Santanu , Victor, Christina Twyman-Saint , Lenz, Heinz‐Josef

Mayo Clinic

Journal for ImmunoTherapy of Cancer | January 22, 2026 | Volume: 14 | Issue: 1 | Pages: e011284

10.1136/jitc-2024-011284 | PMID 41571299 Get It

Background Cysteine–cysteine chemokine receptors 2 (CCR2) and 5 (CCR5) contribute to immune suppression in tumor microenvironments. CCR2 and CCR5 antagonists have demonstrated antitumor activity in pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC), respectively. This phase 1b/2, open-label study evaluated BMS-813160, a CCR2/5 dual antagonist, in combination with chemotherapy±nivolumab in advanced PDAC or metastatic CRC. Methods Part 1 included patients with metastatic untreated (first-line (1L)) PDAC, 1L CRC, or previously treated (second or third line (2/3L)) microsatellite stable (MSS) CRC. Patients received 2 weeks of BMS-813160 monotherapy (300 mg two times a day, 600 mg once daily, 300 mg once daily, or 150 mg once daily) and then BMS-813160+chemotherapy (gemcitabine+nab-paclitaxel (gem/nabP; 1L PDAC), 5-fluorouracil+leucovorin+irinotecan (FOLFIRI; 1L CRC)), or nivolumab (2/3L MSS CRC). Part 2 included patients with metastatic 1L PDAC or 2L CRC. Patients received BMS-813160 300 mg two times a day+gem/nabP±nivolumab (1L PDAC), BMS-813160 300 mg two times a day or 150 mg once daily+FOLFIRI (2L CRC), or chemotherapy alone. Primary endpoints were safety and pharmacodynamics (Part 1) and efficacy (Part 2). Results In Part 1, 22 of 75 (29%) and 54 of 72 (72%) patients experienced a treatment-related adverse event during monotherapy lead-in and overall, respectively. Two dose-limiting toxicities (rash and pericardial effusion with pericarditis, both grade 3) occurred. In Part 2, patients with 1L PDAC who received BMS-813160 300 mg two times a day+gem/nabP+nivolumab achieved an overall response rate (ORR) of 37% (13/35); the median duration of response (DOR) was 45 weeks (95% CI 26.1 to not evaluable). ORRs with BMS-813160 300 mg two times a day+gem/nabP and gem/nabP alone were 26% (9/35) and 28% (9/32), respectively; median DORs were 121 and 31 weeks, respectively. Progression-free survival rates at 24 weeks were 56% (BMS-813160 300 mg two times a day+gem/nabP+nivolumab), 56% (BMS-813160 300 mg two times a day+gem/nabP), and 50% (gem/nabP). ORRs in 2L CRC were 19% (6/32; BMS-813160 300 mg two times a day+FOLFIRI), 13% (4/32; BMS-813160 150 mg once daily+FOLFIRI), and 27% (7/26; FOLFIRI). Conclusions In 1L PDAC, BMS-813160 300 two times a day+gem/nabP±nivolumab demonstrated durable antitumor response and was well tolerated. BMS-813160 combination regimens were tolerable in other cohorts, but clinical efficacy was not demonstrated. Trial registration number NCT03184870 .
Long-term tumor control after Gamma Knife radiosurgery for sporadic vestibular schwannoma
Marinelli, John P. , Daher, Ghazal S. , Khandalavala, Karl R. , Babajanian, Eric E. , Dornhoffer, James R. , Lohse, Christine M., Pollock, Bruce E., Brown, Paul D., Gompel, Jamie J. Van, Celda, María Peris, Neff, Brian A., Driscoll, Colin L. W., Carlson, Matthew L. , Link, Michael J., Lohse, Christine M. , Pollock, Bruce E. , Gompel, Jamie J. Van , Link, Michael J.

Mayo Clinic

Journal of Neurosurgery | January 22, 2026 | Volume: 144 | Issue: 4 | Pages: 965-971

10.3171/2025.8.jns25829 | PMID 41569741 Get It

OBJECTIVE The objective of this study was to describe the long-term efficacy of single-fraction stereotactic radiosurgery (SRS) for the primary treatment of sporadic vestibular schwannoma. METHODS Adult (≥ 18 years of age) patients with sporadic vestibular schwannoma who underwent SRS from 2000 through 2022 were included. RESULTS A total of 749 patients met inclusion criteria, the majority (n = 566, 76%) of whom had tumors extending into the cerebellopontine angle at SRS. The median patient age at SRS was 62 years, half (50%) of the patients were women, and 744 (99%) exhibited House-Brackmann grade I facial nerve function at SRS. A total of 42 patients experienced radiosurgical failure and underwent salvage treatment; the median duration of follow-up for the patients who did not undergo salvage treatment was 7.0 years. Overall tumor control rates (95% CI, number still at risk) at 1, 3, 5, 10, and 15 years after SRS were 100% (100%–100%, 718), 98% (97%–99%, 589), 96% (94%–97%, 464), 92% (90%–95%, 258), and 91% (89%–94%, 125), respectively. Patient age (hazard ratio [HR] for a 10-year increase of 0.92, 95% CI 0.71–1.19; p = 0.5), presence of a macrocystic tumor (HR 0.59, 95% CI 0.14–2.46; p = 0.5), and treated tumor volume (HR for a 1-cm 3 increase of 1.02, 95% CI 0.88–1.18; p = 0.8) were not significantly associated with the risk of salvage. Three distinct post-SRS tumor behavior patterns were observed, with 13% of patients demonstrating tumor pseudoprogression, all but 4 of whom demonstrated pseudoprogression by year 5 post-SRS. CONCLUSIONS SRS demonstrates durable tumor control through 15 years of follow-up in most patients (91%); however, a minority are found to still experience SRS failure even beyond 10 years of surveillance. Although occurring in only a minority of patients, tumor pseudoprogression can be evident out to 5 years or longer post-SRS.
Defining clinically significant tumor size in sporadic vestibular schwannoma to inform timing of radiosurgery during wait-and-scan management: further evidence supporting size threshold surveillance
Carlson, Matthew L. , Marinelli, John P. , Babajanian, Eric E. , Daher, Ghazal S. , Dornhoffer, James R. , Khandalavala, Karl R. , Lohse, Christine M., Gompel, Jamie J. Van, Celda, María Peris, Neff, Brian A., Driscoll, Colin L. W., Link, Michael J., Lohse, Christine M. , Gompel, Jamie J. Van , Link, Michael J.

Mayo Clinic

Journal of Neurosurgery | January 22, 2026 | Volume: 144 | Issue: 4 | Pages: 955-964

10.3171/2025.8.jns25830 | PMID 41569717 Get It

OBJECTIVE Wait-and-scan surveillance is now commonly employed for initial management of small- and medium-sized vestibular schwannomas. Although small differences in tumor size are unlikely to impact outcomes significantly, treatment with either radiosurgery or microsurgery is usually recommended following radiological detection of tumor growth. The objective of the current study was to identify potential inflection points in vestibular schwannoma tumor size, where the risks of treatment with single-fraction stereotactic radiosurgery (SRS) accelerate to inform timing of intervention. METHODS Adult (≥ 18 years old) patients with sporadic vestibular schwannoma who underwent SRS from 2000 through 2022 were included. RESULTS A total of 749 patients with a median age at SRS of 62 years were studied, the majority (n = 566 [76%]) of whom had tumors extending into the cerebellopontine angle (CPA) at SRS. The optimal tumor size cut point to predict SRS failure and need for salvage treatment was 4 mm or more of CPA extension (c-index 0.59, HR 3.60, p = 0.01). The optimal tumor size cut point to predict the outcome of facial nerve paresis was 13 mm or more of CPA extension, resulting in a c-index of 0.63 (HR 2.88, p = 0.01). Among patients with at least 3 months of surveillance before SRS, those with a tumor growth rate ≥ 2.5 mm/year were more likely to undergo salvage treatment than those with a growth rate < 2.5 mm/year, although this difference did not achieve statistical significance (HR 1.82, p = 0.18). CONCLUSIONS The risk of SRS failure requiring salvage treatment and the risk of post-SRS facial nerve paralysis increase at sizes of approximately 4 and 13 mm extension into the CPA, respectively, providing a size threshold anchor to help guide treatment decision-making regarding timing of SRS. Furthermore, rapid tumor growth during the initial wait-and-scan period may be associated with an increased risk of radiosurgical failure, which may influence choice of treatment.
Core outcomes in nerve surgery: development of a core outcome set for lateral femoral cutaneous neuropathy
Wilson, Thomas J., Ali, Zarina S., Desai, Ketan, Garozzo, Debora, Guedes, Fernando, Heinen, Christian P. G., Hong, Jennifer , Jacques, Line G., Jitpun, Ekkapot , Kretschmer, Thomas , Mahan, Mark A., Midha, Rajiv, Puffer, Ross C. , Rasulic, L., Ray, Wilson Z., Rizk, Elias , Rodriguez-Aceves, Carlos A., Shapira, Yuval, Spinner, Robert J., Zager, Eric L. , Wilson, Thomas J. , Ali, Zarina S. , Davis, Gavin A , Dengler, Nora F. , Guedes, Fernando , Heinen, Christian , Jacques, Line , Mahan, Mark A , Midha, Rajiv, Pondaag, Willem , Rasulić, Lukas , Ray, Wilson Z. , Rodríguez-Aceves, Carlos Alberto , Saadeh, Yamaan S. , Socolovsky, Mariano , Spinner, Robert J.

Mayo Clinic

Journal of Neurosurgery | January 22, 2026 | Volume: 144 | Issue: 5 | Pages: 1224-1232

10.3171/2025.8.jns251142 | PMID 41569664 Get It

OBJECTIVE Core outcome sets (COSs) are needed to promote data consistency across studies as well as data synthesis and comparability. The aim of the current study was to use a modified Delphi process to develop a COS for lateral femoral cutaneous neuropathy (LFCN), hereafter COS-LFCN. METHODS A 5-stage approach was used to develop the COS-LFCN: 1) consortium development, 2) literature review to identify potential outcome measures, 3) Delphi survey to develop consensus on outcomes for inclusion, 4) Delphi survey to develop definitions, and 5) consensus meeting to finalize the COS and definitions. This study followed the Core Outcome Set - STAndards for Development, (COS-STAD) recommendations. RESULTS The Core Outcomes in Nerve Surgery (COINS) Consortium comprised 25 participants, all neurological surgeons, representing 14 countries. The final COS-LFCN consisted of 41 factors and outcomes covering domains of demographics, diagnostics, patient-reported outcomes, motor/sensory outcomes, and complications. Appropriate instruments, methods of testing, and definitions were set. The consensus minimum duration of follow-up was 12 months, with the consensus optimal time points for assessment being preoperatively and 3, 6, and 12 months postoperatively. CONCLUSIONS The COINS Consortium developed a consensus COS for LFCN and provided definitions, methods of implementation, and time points for assessment. The COS-LFCN should serve as the minimum data to be collected in all future neurosurgical studies on LFCN. Incorporation of this COS will help improve consistency in reporting, data synthesis and comparability, and minimize outcome reporting bias.
Predictors of achieving Neck Disability Index minimum clinically important difference following cervical deformity surgery
Mikula, Anthony L., Scheer, Justin K., Turner, Jay D., Lafage, Renaud, Lafage, Virginie, Kebaish, Khaled , Klineberg, Eric O., Mundis, Gregory M., Daniels, Alan H., Eastlack, Robert K. , Lewis, Stephen M., Protopsaltis, Themistocles S., Soroceanu, Alex, Gupta, Munish C., Kim, Han Jo, Kelly, Michael P., Lenke, Lawrence G., Shaffrey, Christopher I., Bess, Shay R., Smith, Justin S., Ames, Christopher P., Mikula, Anthony L. , Scheer, Justin K. , Kumar, Rahul Robaish , Turner, Jay D. , Mullin, Jeffrey P. , Lafage, Renaud , Lafage, Virginie , Kebaish, Khaled M. , Klineberg, Eric O. , Mundis, Gregory M. , Daniels, Alan H. , Lewis, Stephen M., Protopsaltis, Themistocles S. , Gupta, Munish C , Kim, Han Jo , Kelly, Michael P. , Lenke, Lawrence G. , Shaffrey, Christopher I. , Bess, Shay R. , Smith, Justin S. , Ames, Christopher Pearson

Mayo Clinic

Journal of Neurosurgery: Spine | January 22, 2026 | Volume: 44 | Issue: 4 | Pages: 581-588

10.3171/2025.9.spine25668 | PMID 41569694 Get It

OBJECTIVE The aim of this study was to determine predictors of the minimum clinically important difference (MCID) in the Neck Disability Index (NDI) following cervical spinal deformity surgery. METHODS A retrospective review was performed of a prospective, multicenter adult cervical spinal deformity database. All patients had baseline and 1-year NDI scores. Patients met MCID with an improvement of NDI by 7 points between baseline and 1 year, as previously established. Baseline demographics, comorbidities, and both baseline and 1-year spinopelvic parameters were evaluated for statistical significance in a univariate logistic regression analysis. Significant variables, in addition to baseline NDI, were analyzed in a multivariable logistic regression model by backward selection with Akaike information criterion minimization. RESULTS A total of 122 patients were included with a median age of 62 (IQR 56, 69) years; 62% of patients were female. Of the 122 patients, 72 (59%) achieved NDI MCID at 1 year. Predictors of achieving MCID on univariate analysis included a lower Charlson Comorbidity Index (CCI) total score (OR 0.70, p = 0.03), depression as a comorbidity (OR 2.9, p = 0.02), lower C2 tilt at the 1-year follow-up (OR 0.92, p = 0.02), and a greater difference between 1-year postoperative C2–7 sagittal vertical axis (SVA) and preoperative C2–7 SVA (OR 0.98, p = 0.0495). On multivariable logistic regression analysis, predictors of achieving MCID included a lower CCI (OR 0.62, p = 0.03), depression as a comorbidity (OR 3.1, p = 0.059), a greater change in C2–7 SVA at the 1-year follow-up compared with baseline (OR 0.97, p = 0.055), and baseline NDI (OR 1.02, p = 0.24) with an area under the curve of 0.74. CONCLUSIONS The best-fit multivariable model included higher baseline NDI, a greater change in C2–7 SVA, patient-reported baseline depression, and lower CCI as important factors in predicting NDI MCID.